Alpha Cognition Inc. Investment Income, Investment Expense
Alpha Cognition Inc. (ACOG) reported Investment Income, Investment Expense of $71.09 thousand for the 3-month period ending 2025-03-31, per its 10-Q filed 2025-05-15.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInvestmentExpense · last filed 2025-05-15
- Alpha Cognition Inc. investment income, investment expense for the quarter ending 2025-03-31 was $71.09K, a 46.86% decline year-over-year.
- Alpha Cognition Inc. investment income, investment expense for the quarter ending 2024-12-31 was $130.42K, a 17.63% decline year-over-year.
- Alpha Cognition Inc. investment income, investment expense for the quarter ending 2024-09-30 was $61.12K.
- Alpha Cognition Inc. investment income, investment expense for the quarter ending 2024-06-30 was $138.56K.
- Alpha Cognition Inc. investment income, investment expense for fiscal 2024 was $463.88K, a 142.76% increase from fiscal 2023.
- Alpha Cognition Inc. investment income, investment expense for fiscal 2023 was $191.09K.
| Period end | Investment Income, Investment Expense 3 month | Investment Income, Investment Expense 6 month | Investment Income, Investment Expense 9 month | Investment Income, Investment Expense 12 month |
|---|---|---|---|---|
| 2025-03-31 | $71.09K 10-Q · filed 2025-05-15 | $201.51K derived: sum of 2 quarters · filed 2025-05-15 | $262.64K derived: sum of 3 quarters · filed 2025-05-15 | $401.20K derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-12-31 | $130.42K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $191.54K derived: sum of 2 quarters · filed 2025-03-31 | $330.10K derived: sum of 3 quarters · filed 2025-03-31 | $463.88K 10-K · filed 2025-03-31 |
| 2024-09-30 | $61.12K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | $199.68K derived: sum of 2 quarters · filed 2024-11-14 | $333.46K 10-Q · filed 2024-11-14 | $491.79K derived: sum of 4 quarters · filed 2025-05-15 |
| 2024-06-30 | $138.56K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-12 | $272.34K 10-Q · filed 2024-08-12 | $430.67K derived: sum of 3 quarters · filed 2025-05-15 | |
| 2024-03-31 | $133.78K 10-Q · filed 2025-05-15 | $292.11K derived: sum of 2 quarters · filed 2025-05-15 | ||
| 2023-12-31 | $158.33K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $191.09K 10-K · filed 2025-03-31 | ||
| 2023-09-30 | $32.76K 10-Q · filed 2024-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Coherus Oncology, Inc. (CHRS) | United States | $0.182B | -1.63 |
| PRECISION BIOSCIENCES INC (DTIL) | United States | $0.175B | -3.95 |
| Voyager Therapeutics, Inc. (VYGR) | United States | $0.173B | -1.99 |
| Protara Therapeutics, Inc. (TARA) | United States | $0.198B | -3.22 |
| Compass Therapeutics, Inc. (CMPX) | United States | $0.204B | -5.35 |
| Acumen Pharmaceuticals, Inc. (ABOS) | United States | $0.162B | -1.83 |
| Outlook Therapeutics, Inc. (OTLK) | United States | $0.162B | -4.90 |
| Alector, Inc. (ALEC) | United States | $0.213B | -1.90 |
| Humacyte, Inc. (HUMA) | United States | $0.155B | -2.26 |
| ANAVEX LIFE SCIENCES CORP. (AVXL) | United States | $0.218B | -18.37 |